Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.49
E. Tejada, P. N. Guindo, S. Portillo-Haro, C. Amores
{"title":"4CPS-217 Netupitant–palonosetron in breast cancer: potential drugs interactions","authors":"E. Tejada, P. N. Guindo, S. Portillo-Haro, C. Amores","doi":"10.1136/EJHPHARM-2021-EAHPCONF.49","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.49","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82883647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.64
L. Barbato, G. Gandini, L. Benda, S. Manfré, P. Marini
{"title":"4CPS-232 Use of dupilumab in the treatment of atopic dermatitis in real clinical practice","authors":"L. Barbato, G. Gandini, L. Benda, S. Manfré, P. Marini","doi":"10.1136/EJHPHARM-2021-EAHPCONF.64","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.64","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85288401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.280
FJ Alonso Zazo, M. Moreno-García, F. Fernández-Fraga, R. Díez-Fernández, T. Molina-García
{"title":"5PSQ-161 Effectiveness and safety of palbociclib and ribociclib","authors":"FJ Alonso Zazo, M. Moreno-García, F. Fernández-Fraga, R. Díez-Fernández, T. Molina-García","doi":"10.1136/EJHPHARM-2021-EAHPCONF.280","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.280","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75953488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.107
I. Patier, F. Fernando, M. Maria, DF Raul, MG Teresa
{"title":"4CPS-275 Efficacy and safety of trifluridine/tipiracil in patients with metastatic colorectal cancer: real world data","authors":"I. Patier, F. Fernando, M. Maria, DF Raul, MG Teresa","doi":"10.1136/EJHPHARM-2021-EAHPCONF.107","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.107","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76705434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.195
T. Leka
{"title":"4CPS-363 Does patient centred care practice improve medication adherence of patients with type 2 diabetes mellitus?","authors":"T. Leka","doi":"10.1136/EJHPHARM-2021-EAHPCONF.195","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.195","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78006577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.131
A. Brincat, P. V. Bonanno, D. Stewart, A. Weidmann
{"title":"4CPS-299 Patients’ misconceptions following initiation of antineoplastic treatment for colorectal cancer","authors":"A. Brincat, P. V. Bonanno, D. Stewart, A. Weidmann","doi":"10.1136/EJHPHARM-2021-EAHPCONF.131","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.131","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75453932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.189
Cantudo Cuenca, Bm Muñoz Cejudo, L. López-Marín, M. Mora, J. Plata
Background and importanceOlder patients living in long term care facilities (LTCFs) were the most vulnerable population during the pandemic caused by SARS-CoV2 It has been estimated that as many as half of all deaths from COVID-19 in Europe occurred in care homes Aim and objectivesTo describe a coordinated programme in response to a COVID-19 outbreak in an LTCF, the clinical and epidemiological characteristics, and the mortality rate Material and methodsThe study was performed from 20 March to 30 June 2020 in a single 264 bed LTCF in Spain In response to the COVID-19 outbreak, we created a multidisciplinary team to implement a coordinated programme to avoid high risk contagion with 12 interventions: (1) training on infection prevention and control, (2) screening of all staff members for symptoms, (3) communal activities and visit restrictions, (4) locating a clean room for equipment, (5) providing personal protective equipment, (6) resident cohorting, (7) assessment of all residents for symptoms and implementation of communication tools with families, (8) strengthening the workforce, (9) provision of equipment, materials and drugs s with a minimum of supplies, (10) establishment of a consultation circuit with the local hospital, (11) compliance of protocols and (12) laboratory testing Demographic, clinical and pharmacological data were retrospectively collected from residents with confirmed SARS-CoV-2 infection: comorbidities, signs and symptoms, outcome (recovery or death), therapy received for COVID-19 and concomitant antibiotic ResultsOf the 231 residents who lived in the LTCF when the first resident with confirmed COVID-19 was tested, 29 4% tested positive for SARS-CoV-2 during the study period, of whom 23 5% died All cause mortality increased by 228 7% compared with the previous 3 years Median Charlson comorbidity index, age adjusted was 6 (IQR 4 5–7) A few confirmed cases were hospitalised (26 5%) and most of these residents died in the local hospital (68 7%) Median duration of hospitalisation was 12 5 days (IQR 3 5–19) Most of the cases (72 1%) had symptoms, often typical symptoms (fever, cough or breathlessness) More than half received any experimental treatment for COVID-19 (58 8%) Antibiotics were prescribed in 52 9%, with an increase of 47 2% in consumption compared with the same period in 2019 Conclusion and relevanceWe detected considerable mortality associated with COVID-19, highlighting the challenges of the implementation of a coordinated programme to control SARS-CoV2 outbreaks in LCTFs reducing hospital referral rates References and/or acknowledgementsConflict of interestNo conflict of interest
{"title":"4CPS-357 Clinical characteristics and mortality of COVID-19 in a long term care facility","authors":"Cantudo Cuenca, Bm Muñoz Cejudo, L. López-Marín, M. Mora, J. Plata","doi":"10.1136/EJHPHARM-2021-EAHPCONF.189","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.189","url":null,"abstract":"Background and importanceOlder patients living in long term care facilities (LTCFs) were the most vulnerable population during the pandemic caused by SARS-CoV2 It has been estimated that as many as half of all deaths from COVID-19 in Europe occurred in care homes Aim and objectivesTo describe a coordinated programme in response to a COVID-19 outbreak in an LTCF, the clinical and epidemiological characteristics, and the mortality rate Material and methodsThe study was performed from 20 March to 30 June 2020 in a single 264 bed LTCF in Spain In response to the COVID-19 outbreak, we created a multidisciplinary team to implement a coordinated programme to avoid high risk contagion with 12 interventions: (1) training on infection prevention and control, (2) screening of all staff members for symptoms, (3) communal activities and visit restrictions, (4) locating a clean room for equipment, (5) providing personal protective equipment, (6) resident cohorting, (7) assessment of all residents for symptoms and implementation of communication tools with families, (8) strengthening the workforce, (9) provision of equipment, materials and drugs s with a minimum of supplies, (10) establishment of a consultation circuit with the local hospital, (11) compliance of protocols and (12) laboratory testing Demographic, clinical and pharmacological data were retrospectively collected from residents with confirmed SARS-CoV-2 infection: comorbidities, signs and symptoms, outcome (recovery or death), therapy received for COVID-19 and concomitant antibiotic ResultsOf the 231 residents who lived in the LTCF when the first resident with confirmed COVID-19 was tested, 29 4% tested positive for SARS-CoV-2 during the study period, of whom 23 5% died All cause mortality increased by 228 7% compared with the previous 3 years Median Charlson comorbidity index, age adjusted was 6 (IQR 4 5–7) A few confirmed cases were hospitalised (26 5%) and most of these residents died in the local hospital (68 7%) Median duration of hospitalisation was 12 5 days (IQR 3 5–19) Most of the cases (72 1%) had symptoms, often typical symptoms (fever, cough or breathlessness) More than half received any experimental treatment for COVID-19 (58 8%) Antibiotics were prescribed in 52 9%, with an increase of 47 2% in consumption compared with the same period in 2019 Conclusion and relevanceWe detected considerable mortality associated with COVID-19, highlighting the challenges of the implementation of a coordinated programme to control SARS-CoV2 outbreaks in LCTFs reducing hospital referral rates References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74865564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.182
M. Saura, P. Pacheco-López, C. F. Zamora, S. Bautista, N. Pérez
{"title":"4CPS-350 Role of the pharmacist in internal medicine: analysis of pharmaceutical interventions during a rotation in an internal medicine department","authors":"M. Saura, P. Pacheco-López, C. F. Zamora, S. Bautista, N. Pérez","doi":"10.1136/EJHPHARM-2021-EAHPCONF.182","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.182","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74197415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.89
I. García, M. J. Cuéllar‐Monreal, M. Centelles-Oria, T. Palanques-Pastor, E. Monte-Boquet, A. García‐Robles, M. V. Tarazona‐Casany, J. Poveda-Andrés, R. Iglesias-Gómez, O. Ballesta-López, A. Solana-Altabella
{"title":"4CPS-257 Relevance of ritonavir interactions in HIV treatments that involve treatment modification","authors":"I. García, M. J. Cuéllar‐Monreal, M. Centelles-Oria, T. Palanques-Pastor, E. Monte-Boquet, A. García‐Robles, M. V. Tarazona‐Casany, J. Poveda-Andrés, R. Iglesias-Gómez, O. Ballesta-López, A. Solana-Altabella","doi":"10.1136/EJHPHARM-2021-EAHPCONF.89","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.89","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74812673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-01DOI: 10.1136/EJHPHARM-2021-EAHPCONF.173
O. Reshetko, A. Grishin
{"title":"4CPS-341 The role of pharmacists in providing pharmaceutical care for patients with headaches","authors":"O. Reshetko, A. Grishin","doi":"10.1136/EJHPHARM-2021-EAHPCONF.173","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.173","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73677478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：